2024

Radiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation
Adolph J, Fleischhack G, Tschirner S, Rink L, Dittes C, Mikasch R, Dammann P, Mynarek M, Obrecht-Sturm D, Rutkowski S, Bison B, Warmuth-Metz M, Pietsch T, Pfister S, Pajtler K, Milde T, Kortmann R, Dietzsch S, Timmermann B, Tippelt S
CANCERS. 2024;16(11):.

Classification of Brain Tumors by Nanopore Sequencing of Cell-Free DNA from Cerebrospinal Fluid
Afflerbach A, Rohrandt C, Brändl B, Sönksen M, Hench J, Frank S, Börnigen D, Alawi M, Mynarek M, Winkler B, Ricklefs F, Synowitz M, Dührsen L, Rutkowski S, Wefers A, Müller F, Schoof M, Schüller U
CLIN CHEM. 2024;70(1):250-260.

Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level
Godbole S, Voß H, Gocke A, Schlumbohm S, Schumann Y, Peng B, Mynarek M, Rutkowski S, Dottermusch M, Dorostkar M, Korshunov A, Mair T, Pfister S, Kwiatkowski M, Hotze M, Neumann P, Hartmann C, Weis J, Liesche-Starnecker F, Guan Y, Moritz M, Siebels B, Struve N, Schlüter H, Schüller U, Krisp C, Neumann J
NAT COMMUN. 2024;15(1):6237.

Child-centredness in paediatric magnetic resonance imaging: Information needs and experiences of children requiring magnetic resonance imaging and their parents
Inhestern L, Herrmann J, Schürmann J, Meister R, Nawka M, Mynarek M, Linhart D, Bergelt C
CHILD CARE HLTH DEV. 2024;50(1):e13157.

Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation
Neyazi S, Yamazawa E, Hack K, Tanaka S, Nagae G, Kresbach C, Umeda T, Eckhardt A, Tatsuno K, Pohl L, Hana T, Bockmayr M, Kim P, Dorostkar M, Takami T, Obrecht D, Takai K, Suwala A, Komori T, Godbole S, Wefers A, Otani R, Neumann J, Higuchi F, Schweizer L, Nakanishi Y, Monoranu C, Takami H, Engertsberger L, Yamada K, Ruf V, Nomura M, Mohme T, Mukasa A, Herms J, Takayanagi S, Mynarek M, Matsuura R, Lamszus K, Ishii K, Kluwe L, Imai H, von Deimling A, Koike T, Benesch M, Kushihara Y, Snuderl M, Nambu S, Frank S, Omura T, Hagel C, Kugasawa K, Mautner V, Ichimura K, Rutkowski S, Aburatani H, Saito N, Schüller U
ACTA NEUROPATHOL. 2024;147(1):22.

Pineal anlage tumor: clinical and diagnostic features, and rationales for treatment
Obrecht-Sturm D, Pfaff E, Mynarek M, Bison B, Rodehüser M, Becker M, Kietz S, Pfister S, Jones D, Sturm D, von Deimling A, Sahm F, Kortmann R, Schwarz R, Pietsch T, Fleischhack G, Rutkowski S
J NEURO-ONCOL. 2024;166(2):359-368.

Survivors of infant atypical teratoid/rhabdoid tumors present with severely impaired cognitive functions especially for fluid intelligence and visual processing: data from the German brain tumor studies
Traunwieser T, Loos E, Ottensmeier H, Gastberger K, Nemes K, Mynarek M, Bison B, Kandels D, Neumayer P, Neumann-Holbeck A, Lüttich P, Baust K, Faulstich-Ritter K, John R, Kreisch A, Landmann J, Manteufel E, Nest A, Prüfe J, Schubert L, Stamm W, Timmermann B, Gerss J, Rutkowski S, Schlegel P, Eyrich M, Gnekow A, Frühwald M
PEDIATR BLOOD CANCER. 2024;71(5):e30910.

2023

G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells
Cetin M, Rieckmann T, Hoffer K, Riepen B, Christiansen S, Gatzemeier F, Feyerabend S, Schoof M, Schüller U, Petersen C, Mynarek M, Rothkamm K, Kriegs M, Struve N
RADIAT ONCOL. 2023;18(1):.

Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study
Erker C, Mynarek M, Bailey S, Mazewski C, Baroni L, Massimino M, Hukin J, Aguilera D, Cappellano A, Ramaswamy V, Lassaletta A, Perreault S, Kline C, Rajagopal R, Michaiel G, Zapotocky M, Santa-Maria Lopez V, La Madrid A, Cacciotti C, Sandler E, Hoffman L, Klawinski D, Khan S, Salloum R, Hoppmann A, Larouche V, Dorris K, Toledano H, Gilheeney S, Abdelbaki M, Wilson B, Tsang D, Knipstein J, Oren M, Shah S, Murray J, Ginn K, Wang Z, Fleischhack G, Obrecht D, Tonn S, Harrod V, Matheson K, Crooks B, Strother D, Cohen K, Hansford J, Mueller S, Margol A, Gajjar A, Dhall G, Finlay J, Northcott P, Rutkowski S, Clifford S, Robinson G, Bouffet E, Lafay-Cousin L
J CLIN ONCOL. 2023;41(10):1921-1932.

Mitochondrial DNA mutations in Medulloblastoma
Funke V, Sandmann S, Melcher V, Seggewiss J, Horvath J, Jäger N, Kool M, Jones D, Pfister S, Milde T, Rutkowski S, Mynarek M, Varghese J, Sträter R, Rust S, Seelhöfer A, Reunert J, Fiedler B, Schüller U, Marquardt T, Kerl K
ACTA NEUROPATHOL COM. 2023;11(1):124.

Group-specific cellular metabolism in Medulloblastoma
Funke V, Walter C, Melcher V, Wei L, Sandmann S, Hotfilder M, Varghese J, Jäger N, Kool M, Jones D, Pfister S, Milde T, Mynarek M, Rutkowski S, Seggewiss J, Jeising D, de Faria F, Marquardt T, Albert T, Schüller U, Kerl K
J TRANSL MED. 2023;21(1):363.

Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome
Kolodziejczak A, Guerrini-Rousseau L, Planchon J, Ecker J, Selt F, Mynarek M, Obrecht D, Sill M, Autry R, Zhao E, Hirsch S, Amouyal E, Dufour C, Ayrault O, Torrejon J, Waszak S, Ramaswamy V, Pentikainen V, Demir H, Clifford S, Schwalbe E, Massimi L, Snuderl M, Galbraith K, Karajannis M, Hill K, Li B, Walsh M, White C, Redmond S, Loizos L, Jakob M, Kordes U, Schmid I, Hauer J, Blattmann C, Filippidou M, Piccolo G, Scheurlen W, Farrag A, Grund K, Sutter C, Pietsch T, Frank S, Schewe D, Malkin D, Ben-Arush M, Sehested A, Wong T, Wu K, Liu Y, Carceller F, Mueller S, Stoller S, Taylor M, Tabori U, Bouffet E, Kool M, Sahm F, von Deimling A, Korshunov A, von Hoff K, Kratz C, Sturm D, Jones D, Rutkowski S, van Tilburg C, Witt O, Bougeard G, Pajtler K, Pfister S, Bourdeaut F, Milde T
NEURO-ONCOLOGY. 2023;25(12):2273-2286.

Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes
Korshunov A, Okonechnikov K, Schrimpf D, Tonn S, Mynarek M, Koster J, Sievers P, Milde T, Sahm F, Jones D, von Deimling A, Pfister S, Kool M
ACTA NEUROPATHOL. 2023;145(6):829-842.

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts
Mynarek M, Obrecht D, Sill M, Sturm D, Kloth-Stachnau K, Selt F, Ecker J, von Hoff K, Juhnke B, Goschzik T, Pietsch T, Bockmayr M, Kool M, von Deimling A, Witt O, Schüller U, Benesch M, Gerber N, Sahm F, Jones D, Korshunov A, Pfister S, Rutkowski S, Milde T
ACTA NEUROPATHOL. 2023;145(1):97-112.

A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymoma
Ng C, Obrecht D, Wells O, Zapotocky M, Sumerauer D, Coltin H, Khuong-Quang D, Eisenstat D, Kinross K, White C, Algar E, Luck A, Witt H, Schüller U, Mynarek M, Pietsch T, Gerber N, Benesch M, Warmuth-Metz M, Kortmann R, Bison B, Taylor M, Rutkowski S, Pfister S, Jones D, Gottardo N, von Hoff K, Pajtler K, Ramaswamy V, Hansford J
NEURO-ONCOL ADV. 2023;5(1):vdad057.

Kinder und Jugendliche mit intrakraniellem Ependymom – Empfehlungen der HIT-MED-Studiengruppe der GPOH zur Erstlinientherapie
Obrecht D, Mynarek M, Stickan-Verfürth M, Bison B, Schüller U, Pajtler K, Hagel C, Thomale U, Fleischhack G, Timmermann B, Rutkowski S
KLIN PADIATR. 2023;235(3):167-177.

Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures
Schoof M, Godbole S, Albert T, Dottermusch M, Walter C, Ballast A, Qin N, Olivera M, Göbel C, Neyazi S, Holdhof D, Kresbach C, Peter L, Epplen G, Thaden V, Spohn M, Blattner-Johnson M, Modemann F, Mynarek M, Rutkowski S, Sill M, Varghese J, Afflerbach A, Eckhardt A, Münter D, Verma A, Struve N, Jones D, Remke M, Neumann J, Kerl K, Schüller U
NAT COMMUN. 2023;14(1):7717.

Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology
Sturm D, Capper D, Andreiuolo F, Gessi M, Kölsche C, Reinhardt A, Sievers P, Wefers A, Ebrahimi A, Suwala A, Gielen G, Sill M, Schrimpf D, Stichel D, Hovestadt V, Daenekas B, Rode A, Hamelmann S, Previti C, Jäger N, Buchhalter I, Blattner-Johnson M, Jones B, Warmuth-Metz M, Bison B, Grund K, Sutter C, Hirsch S, Dikow N, Hasselblatt M, Schüller U, Gerber N, White C, Buntine M, Kinross K, Algar E, Hansford J, Gottardo N, Hernáiz Driever P, Gnekow A, Witt O, Müller H, Calaminus G, Fleischhack G, Kordes U, Mynarek M, Rutkowski S, Frühwald M, Kramm C, von Deimling A, Pietsch T, Sahm F, Pfister S, Jones D
NAT MED. 2023;29(4):917-926.

Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy
Tonn S, Korshunov A, Obrecht D, Sill M, Spohn M, von Hoff K, Milde T, Pietsch T, Goschzik T, Bison B, Juhnke B, Struve N, Sturm D, Sahm F, Bockmayr M, Friedrich C, von Bueren A, Gerber N, Benesch M, Jones D, Kool M, Wefers A, Schüller U, Pfister S, Rutkowski S, Mynarek M
NEURO-ONCOLOGY. 2023;25(8):1518-1529.

2022

MR Imaging and Clinical Characteristics of Diffuse Glioneuronal Tumor with Oligodendroglioma-like Features and Nuclear Clusters
Benesch M, Perwein T, Apfaltrer G, Langer T, Neumann A, Brecht I, Schuhmann M, Cario H, Frühwald M, Vollert K, van Buiren M, Deng M, Seitz A, Haberler C, Mynarek M, Kramm C, Sahm F, Robe P, Dankbaar J, Hoff K, Warmuth-Metz M, Bison B
AM J NEURORADIOL. 2022;43(10):1523-1529.

Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease
Bockmayr M, Harnisch K, Pohl L, Schweizer L, Mohme T, Körner M, Alawi M, Suwala A, Dorostkar M, Monoranu C, Hasselblatt M, Wefers A, Capper D, Hench J, Frank S, Richardson T, Tran I, Liu E, Snuderl M, Engertsberger L, Benesch M, von Deimling A, Obrecht D, Mynarek M, Rutkowski S, Glatzel M, Neumann J, Schüller U
NEURO-ONCOLOGY. 2022;24(10):1689-1699.

Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients
Diaz Coronado R, Mynarek M, Koelsche C, Mora Alferez P, Casavilca Zambrano S, Wachtel Aptowitzer A, Sahm F, von Deimling A, Schüller U, Spohn M, Sturm D, Pfister S, Morales La Madrid A, Sernaque Quintana R, Sarria Bardales G, Negreiros Chinchihuara T, Ojeda Medina L, Garcia-Corrochano Medina P, Campos Sanchez D, Ponce Farfan J, Rutkowski S, Garcia Leon J
CANCER-AM CANCER SOC. 2022;128(4):697-707.

Types of deviation and review criteria in pretreatment central quality control of tumor bed boost in medulloblastoma-an analysis of the German Radiotherapy Quality Control Panel in the SIOP PNET5 MB trial
Dietzsch S, Braesigk A, Seidel C, Remmele J, Kitzing R, Schlender T, Mynarek M, Geismar D, Jablonska K, Schwarz R, Pazos M, Weber D, Frick S, Gurtner K, Matuschek C, Harrabi S, Glück A, Lewitzki V, Dieckmann K, Benesch M, Gerber N, Obrecht D, Rutkowski S, Timmermann B, Kortmann R
STRAHLENTHER ONKOL. 2022;198(3):282-290.

Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study
Gaab C, Adolph J, Tippelt S, Mikasch R, Obrecht D, Mynarek M, Rutkowski S, Pfister S, Milde T, Witt O, Bison B, Warmuth-Metz M, Kortmann R, Dietzsch S, Pietsch T, Timmermann B, Sträter R, Bode U, Faldum A, Kwiecien R, Fleischhack G
CANCERS. 2022;14(3):.

Genetic alterations of TP53 and OTX2 indicate increased risk of relapse in WNT medulloblastomas
Goschzik T, Mynarek M, Doerner E, Schenk A, Spier I, Warmuth-Metz M, Bison B, Obrecht D, Struve N, Kortmann R, Schmid M, Aretz S, Rutkowski S, Pietsch T
ACTA NEUROPATHOL. 2022;144(6):1143-1156.

Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial
Hagel C, Sloman V, Mynarek M, Petrasch K, Obrecht D, Kühl J, Deinlein F, Schmid R, von Bueren A, Friedrich C, Juhnke B, Gerber N, Kwiecien R, Girschick H, Höller A, Zapf A, von Hoff K, Rutkowski S
EUR J CANCER. 2022;164:30-38.

Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial
Juhnke B, Gessi M, Gerber N, Friedrich C, Mynarek M, von Bueren A, Haberler C, Schüller U, Kortmann R, Timmermann B, Bison B, Warmuth-Metz M, Kwiecien R, Pfister S, Spix C, Pietsch T, Kool M, Rutkowski S, von Hoff K
NEURO-ONCOLOGY. 2022;24(1):127-137.

Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression
Korshunov A, Okonechnikov K, Stichel D, Schrimpf D, Delaidelli A, Tonn S, Mynarek M, Sievers P, Sahm F, Jones D, von Deimling A, Pfister S, Kool M
ACTA NEUROPATHOL. 2022;144(2):339-352.

Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies
Obrecht D, Mynarek M, Hagel C, Kwiecien R, Spohn M, Bockmayr M, Bison B, Pfister S, Jones D, Sturm D, von Deimling A, Sahm F, von Hoff K, Juhnke B, Benesch M, Gerber N, Friedrich C, von Bueren A, Kortmann R, Schwarz R, Pietsch T, Fleischhack G, Schüller U, Rutkowski S
J NEURO-ONCOL. 2022;157(1):37-48.

2021

Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies
Adolph J, Fleischhack G, Gaab C, Mikasch R, Mynarek M, Rutkowski S, Schüller U, Pfister S, Pajtler K, Milde T, Witt O, Bison B, Warmuth-Metz M, Kortmann R, Dietzsch S, Pietsch T, Timmermann B, Tippelt S
J NEURO-ONCOL. 2021;155(2):193-202.

Local and Systemic Therapy of Recurrent Ependymoma in Children and Adolescents: Short- and Long-term Results of the E-HIT-REZ 2005 Study
Adolph J, Fleischhack G, Mikasch R, Zeller J, Warmuth-Metz M, Bison B, Mynarek M, Rutkowski S, Schüller U, von Hoff K, Obrecht D, Pietsch T, Pfister S, Pajtler K, Witt O, Witt H, Kortmann R, Timmermann B, Krauß J, Frühwald M, Faldum A, Kwiecien R, Bode U, Tippelt S
NEURO-ONCOLOGY. 2021;23(6):1012-1023.

Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma: First experiences of the German radiotherapy quality control panel in the SIOP PNET5 MB trial
Dietzsch S, Braesigk A, Seidel C, Remmele J, Kitzing R, Schlender T, Mynarek M, Geismar D, Jablonska K, Schwarz R, Pazos M, Walser M, Frick S, Gurtner K, Matuschek C, Harrabi S, Glück A, Lewitzki V, Dieckmann K, Benesch M, Gerber N, Rutkowski S, Timmermann B, Kortmann R
STRAHLENTHER ONKOL. 2021;197(8):674-682.

Detailed Clinical and Histopathological Description of 8 Cases of Molecularly Defined CNS Neuroblastomas
Holsten T, Lubieniecki F, Spohn M, Mynarek M, Bison B, Löbel U, Rutkowski S, Schüller U
J NEUROPATH EXP NEUR. 2021;80(1):52-59.

Defining the Spectrum, Treatment and Outcome of Patients With Genetically Confirmed Gorlin Syndrome From the HIT-MED Cohort
Kloth K, Obrecht D, Sturm D, Pietsch T, Warmuth-Metz M, Bison B, Mynarek M, Rutkowski S
FRONT ONCOL. 2021;11:.

Sarcoma classification by DNA methylation profiling
Koelsche C, Schrimpf D, Stichel D, Sill M, Sahm F, Reuss D, Blattner M, Worst B, Heilig C, Beck K, Horak P, Kreutzfeldt S, Paff E, Stark S, Johann P, Selt F, Ecker J, Sturm D, Pajtler K, Reinhardt A, Wefers A, Sievers P, Ebrahimi A, Suwala A, Fernández-Klett F, Casalini B, Korshunov A, Hovestadt V, Kommoss F, Kriegsmann M, Schick M, Bewerunge-Hudler M, Milde T, Witt O, Kulozik A, Kool M, Romero-Pérez L, Grünewald T, Kirchner T, Wick W, Platten M, Unterberg A, Uhl M, Abdollahi A, Debus J, Lehner B, Thomas C, Hasselblatt M, Paulus W, Hartmann C, Staszewski O, Prinz M, Hench J, Frank S, Versleijen-Jonkers Y, Weidema M, Mentzel T, Griewank K, de Álava E, Martín J, Gastearena M, Chang K, Low S, Cuevas-Bourdier A, Mittelbronn M, Mynarek M, Rutkowski S, Schüller U, Mautner V, Schittenhelm J, Serrano J, Snuderl M, Büttner R, Klingebiel T, Buslei R, Gessler M, Wesseling P, Dinjens W, Brandner S, Jaunmuktane Z, Lyskjær I, Schirmacher P, Stenzinger A, Brors B, Glimm H, Heining C, Tirado O, Sáinz-Jaspeado M, Mora J, Alonso J, Del Muro X, Moran S, Esteller M, Benhamida J, Ladanyi M, Wardelmann E, Antonescu C, Flanagan A, Dirksen U, Hohenberger P, Baumhoer D, Hartmann W, Vokuhl C, Flucke U, Petersen I, Mechtersheimer G, Capper D, Jones D, Fröhling S, Pfister S, von Deimling A
NAT COMMUN. 2021;12(1):498.

Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype
Kresbach C, Dorostkar M, Suwala A, Wefers A, Schweizer L, Engertsberger L, Bison B, Mynarek M, Kloth-Stachnau K, Spohn M, von Deimling A, Benesch M, Hagel C, Mautner V, Rutkowski S, Schüller U
ACTA NEUROPATHOL. 2021;141(6):971-974.

Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study
Liu A, Li B, Pfaff E, Gudenas B, Vasiljevic A, Orr B, Dufour C, Snuderl M, Karajannis M, Rosenblum M, Hwang E, Ng H, Hansford J, Szathmari A, Faure-Conter C, Merchant T, Levine M, Bouvier N, von Hoff K, Mynarek M, Rutkowski S, Sahm F, Kool M, Hawkins C, Onar-Thomas A, Robinson G, Gajjar A, Pfister S, Bouffet E, Northcott P, Jones D, Huang A
ACTA NEUROPATHOL. 2021;141(5):771-785.

SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma
Mynarek M, Milde T, Padovani L, Janssens G, Kwiecien R, Mosseri V, Clifford S, Doz F, Rutkowski S
CANCERS. 2021;13(23):.

Follow-up evaluation of a web-based pediatric brain tumor board in Latin America
Rosabal-Obando M, Osorio D, Lassaletta A, La Madrid A, Bartels U, Finlay J, Qaddoumi I, Rutkowski S, Mynarek M
PEDIATR BLOOD CANCER. 2021;68(9):e29073.

Diagnostics and Diagnosis of Late Effects in Childhood Brain Tumour Survivors
Tallen G, Mynarek M, Tischler T, Weller M, Rutkowski S
2021. Late Treatment Effects and Cancer Survivor Care in the Young. Beck J, Bokemeyer C, Langer T (Hrsg.). 1. Aufl. Cham: Springer Nature Switzerland, 239-251.

Therapeutic implications of improved molecular diagnostics for rare CNS-embryonal tumor entities: results of an international, retrospective study
von Hoff K, Haberler C, Schmitt-Hoffner F, Schepke E, de Rojas T, Jacobs S, Zapotocky M, Sumerauer D, Perek-Polnik M, Dufour C, van Vuurden D, Slavc I, Gojo J, Pickles J, Gerber N, Massimino M, Gil-da-Costa M, Garami M, Kumirova E, Sehested A, Scheie D, Cruz O, Moreno L, Cho J, Zeller B, Bovenschen N, Grotzer M, Alderete D, Snuderl M, Zheludkova O, Golanov A, Okonechnikov K, Mynarek M, Juhnke B, Rutkowski S, Schüller U, Pizer B, Zezschwitz B, Kwiecien R, Wechsung M, Konietschke F, Hwang E, Sturm D, Pfister S, von Deimling A, Rushing E, Ryzhova M, Hauser P, Łastowska M, Wesseling P, Giangaspero F, Hawkins C, Figarella-Branger D, Eberhart C, Burger P, Gessi M, Korshunov A, Jacques T, Capper D, Pietsch T, Kool M
NEURO-ONCOLOGY. 2021;23(9):1597-1611.

Supratentorial ependymoma in childhood: more than just RELA or YAP
Zschernack V, Jünger S, Mynarek M, Rutkowski S, Garre M, Ebinger M, Neu M, Faber J, Erdlenbruch B, Claviez A, Bielack S, Brozou T, Frühwald M, Dörner E, Dreschmann V, Stock A, Solymosi L, Hench J, Frank S, Vokuhl C, Waha A, Andreiuolo F, Pietsch T
ACTA NEUROPATHOL. 2021;141(3):455-466.

2020

Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma
Begemann M, Waszak S, Robinson G, Jäger N, Sharma T, Knopp C, Kraft F, Moser O, Mynarek M, Guerrini-Rousseau L, Brugieres L, Varlet P, Pietsch T, Bowers D, Chintagumpala M, Sahm F, Korbel J, Rutkowski S, Eggermann T, Gajjar A, Northcott P, Elbracht M, Pfister S, Kontny U, Kurth I
J CLIN ONCOL. 2020;38(1):43-50.

Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma - A Report From the HIT 2000 Trial
Dietzsch S, Placzek F, Pietschmann K, von Bueren A, Matuschek C, Glück A, Guckenberger M, Budach V, Welzel J, Pöttgen C, Schmidberger H, Heinzelmann F, Paulsen F, Escudero M, Schwarz R, Hornung D, Martini C, Grosu A, Stueben G, Jablonska K, Dunst J, Stranzl-Lawatsch H, Dieckmann K, Timmermann B, Pietsch T, Warmuth-Metz M, Bison B, Kwiecien R, Benesch M, Gerber N, Grotzer M, Pfister S, Clifford S, von Hoff K, Klagges S, Rutkowski S, Kortmann R, Mynarek M
ADV RADIAT ONCOL. 2020;5(6):1158-1169.

Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome
Jünger S, Andreiuolo F, Mynarek M, Dörner E, Zur Mühlen A, Rutkowski S, von Bueren A, Pietsch T
CHILD NERV SYST. 2020;36(11):2693-2700.

CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort
Jünger S, Andreiuolo F, Mynarek M, Wohlers I, Rahmann S, Klein-Hitpass L, Dörner E, Zur Mühlen A, Velez-Char N, von Hoff K, Warmuth-Metz M, Kortmann R, Timmermann B, von Bueren A, Rutkowski S, Pietsch T
ACTA NEUROPATHOL. 2020;140(3):405-407.

Young children with medulloblastoma: Important open questions and the high-risk dilemma
Mynarek M, Rutkowski S
NEURO-ONCOLOGY. 2020;22(12):1723-1724.

Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort
Mynarek M, von Hoff K, Pietsch T, Ottensmeier H, Warmuth-Metz M, Bison B, Pfister S, Korshunov A, Sharma T, Jaeger N, Ryzhova M, Zheludkova O, Golanov A, Rushing E, Hasselblatt M, Koch A, Schüller U, von Deimling A, Sahm F, Sill M, Riemenschneider M, Dohmen H, Monoranu C, Sommer C, Staszewski O, Mawrin C, Schittenhelm J, Brück W, Filipski K, Hartmann C, Meinhardt M, Pietschmann K, Haberler C, Slavc I, Gerber N, Grotzer M, Benesch M, Schlegel P, Deinlein F, von Bueren A, Friedrich C, Juhnke B, Obrecht D, Fleischhack G, Kwiecien R, Faldum A, Kortmann R, Kool M, Rutkowski S
J CLIN ONCOL. 2020;38(18):2028-2040.

Molecular characterization of histopathological ependymoma variants
Neumann J, Spohn M, Obrecht D, Mynarek M, Thomas C, Hasselblatt M, Dorostkar M, Wefers A, Frank S, Monoranu C, Koch A, Witt H, Kool M, Pajtler K, Rutkowski S, Glatzel M, Schüller U
ACTA NEUROPATHOL. 2020;139(2):305-318.

Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations
Pfaff E, Aichmüller C, Sill M, Stichel D, Snuderl M, Karajannis M, Schuhmann M, Schittenhelm J, Hasselblatt M, Thomas C, Korshunov A, Rhizova M, Wittmann A, Kaufhold A, Iskar M, Ketteler P, Lohmann D, Orr B, Ellison D, von Hoff K, Mynarek M, Rutkowski S, Sahm F, von Deimling A, Lichter P, Kool M, Zapatka M, Pfister S, Jones D
ACTA NEUROPATHOL. 2020;139(2):243-257.

2019

Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series
Benesch M, Mynarek M, Witt H, Warmuth-Metz M, Pietsch T, Bison B, Pfister S, Pajtler K, Kool M, Schüller U, Pietschmann K, Juhnke B, Tippelt S, Fleischhack G, Schmid I, Kramm C, Vorwerk P, Beilken A, Classen C, Hernáiz Driever P, Kropshofer G, Imschweiler T, Lemmer A, Kortmann R, Rutkowski S, von Hoff K
ONCOLOGIST. 2019;24(9):e921-e929.

Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort
Jünger S, Mynarek M, Wohlers I, Dörner E, Mühlen A, Velez-Char N, von Hoff K, Rutkowski S, Warmuth-Metz M, Kortmann R, Timmermann B, Rahmann S, Klein-Hitpass L, von Bueren A, Pietsch T
ACTA NEUROPATHOL COM. 2019;7(1):181.

Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes
Sharma T, Schwalbe E, Williamson D, Sill M, Hovestadt V, Mynarek M, Rutkowski S, Robinson G, Gajjar A, Cavalli F, Ramaswamy V, Taylor M, Lindsey J, Hill R, Jäger N, Korshunov A, Hicks D, Bailey S, Kool M, Chavez L, Northcott P, Pfister S, Clifford S
ACTA NEUROPATHOL. 2019;138(2):309-326.

Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort
Stock A, Mynarek M, Pietsch T, Pfister S, Clifford S, Goschzik T, Sturm D, Schwalbe E, Hicks D, Rutkowski S, Bison B, Pham M, Warmuth-Metz M
AM J NEURORADIOL. 2019;40(11):1811-1817.

2018

Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations
Koelsche C, Mynarek M, Schrimpf D, Bertero L, Serrano J, Sahm F, Reuss D, Hou Y, Baumhoer D, Vokuhl C, Flucke U, Petersen I, Brück W, Rutkowski S, Zambrano S, Garcia Leon J, Diaz Coronado R, Gessler M, Tirado O, Mora J, Alonso J, Garcia Del Muro X, Esteller M, Sturm D, Ecker J, Milde T, Pfister S, Korshunov A, Snuderl M, Mechtersheimer G, Schüller U, Jones D, von Deimling A
ACTA NEUROPATHOL. 2018;136(2):327-337.

2017

Refining medulloblastoma subgroups
Juhnke B, Mynarek M, Rutkowski S
LANCET ONCOL. 2017;18(7):847-848.

Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data
Mynarek M, Pizer B, Dufour C, van Vuurden D, Garami M, Massimino M, Fangusaro J, Davidson T, Gil-da-Costa M, Sterba J, Benesch M, Gerber N, Juhnke B, Kwiecien R, Pietsch T, Kool M, Clifford S, Ellison D, Giangaspero F, Wesseling P, Gilles F, Gottardo N, Finlay J, Rutkowski S, von Hoff K
NEURO-ONCOLOGY. 2017;19(4):576-585.

2016

Pubertal Development in Pediatric Kidney Transplant Patients Receiving Mammalian Target of Rapamycin Inhibitors or Conventional Immunosuppression
Förster J, Ahlenstiel-Grunow T, Zapf A, Mynarek M, Pape L
TRANSPLANTATION. 2016;100(11):2461-2470.

Reply to letter that comments on 'Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy'
Pompe R, von Bueren A, Mynarek M, von Hoff K, Rutkowski S
EUR J CANCER. 2016;56:181-2.

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis
Ramaswamy V, Hielscher T, Mack S, Lassaletta A, Lin T, Pajtler K, Jones D, Luu B, Cavalli F, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon R, Lipp E, Dunham C, Hukin J, Eisenstat D, Fulton D, van Landeghem F, Santi M, van Veelen M, Van Meir E, Osuka S, Fan X, Muraszko K, Tirapelli D, Oba-Shinjo S, Marie S, Carlotti C, Lee J, Rao A, Giannini C, Faria C, Nunes S, Mora J, Hamilton R, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian R, Olson J, Leonard J, Gardner C, Grajkowska W, Chambless L, Cain J, Eberhart C, Ahsan S, Massimino M, Giangaspero F, Buttarelli F, Packer R, Emery L, Yong W, Soto H, Liau L, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis M, Zagzag D, Wheeler H, von Hoff K, Alonso M, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan J, Guzman M, Elbabaa S, Colman H, Dhall G, Fisher P, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro A, Pollack I, Prados M, Robins H, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins C, Rutka J, Dirks P, Pfister S, Merchant T, Gilbert M, Armstrong T, Korshunov A, Ellison D, Taylor M
J CLIN ONCOL. 2016;34(21):2468-77.

Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters
von Bueren A, Kortmann R, von Hoff K, Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber N, Warmuth-Metz M, Soerensen N, Deinlein F, Benesch M, Zwiener I, Kwiecien R, Faldum A, Bode U, Fleischhack G, Hovestadt V, Kool M, Jones D, Northcott P, Kuehl J, Pfister S, Pietsch T, Rutkowski S
J CLIN ONCOL. 2016;34(34):4151-4160.

2015

Generation of high-titre virus stocks using BrK.219, a B-cell line infected stably with recombinant Kaposi's sarcoma-associated herpesvirus
Kati S, Hage E, Mynarek M, Ganzenmueller T, Indenbirken D, Grundhoff A, Schulz T
J VIROL METHODS. 2015;217:79-86.

Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy
Pompe R, von Bueren A, Mynarek M, von Hoff K, Friedrich C, Kwiecien R, Treulieb W, Lindow C, Deinlein F, Fleischhack G, Kuehl J, Rutkowski S
EUR J CANCER. 2015;51(17):2634-2642.

Strategies to improve the quality of survival for childhood brain tumour survivors
Tallen G, Resch A, Calaminus G, Wiener A, Leiss U, Pletschko T, Friedrich C, Langer T, Grabow D, Driever P, Kortmann R, Timmermann B, Pietsch T, Warmuth-Metz M, Bison B, Thomale U, Krauss J, Mynarek M, von Hoff K, Ottensmeier H, Frühwald M, Kramm C, Temming P, Müller H, Witt O, Kordes U, Fleischhack G, Gnekow A, Rutkowski S
EUR J PAEDIATR NEURO. 2015;19(6):619-39.

2014

Recent developments and current concepts in medulloblastoma
Gerber N, Mynarek M, von Hoff K, Friedrich C, Resch A, Rutkowski S
CANCER TREAT REV. 2014;40(3):356-365.

Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies
Müller K, Mynarek M, Zwiener I, Siegler N, Zimmermann M, Christiansen H, Budach W, Henke G, Warmuth-Metz M, Pietsch T, von Hoff K, von Bueren A, Bode U, Rutkowski S, Kortmann R, Fleischhack G, Tippelt S
INT J RADIAT ONCOL. 2014;88(5):1019-1024.

Patient, virus, and treatment-related risk factors in pediatric adenovirus infection after stem cell transplantation: results of a routine monitoring program
Mynarek M, Ganzenmueller T, Mueller-Heine A, Mielke C, Gonnermann A, Beier R, Sauer M, Eiz-Vesper B, Kohstall U, Sykora K, Heim A, Maecker-Kolhoff B
BIOL BLOOD MARROW TR. 2014;20(2):250-6.

Hochrisiko-Medulloblastom: Erfahrungen aus HIT2000
Mynarek M, von Hoff K, Kortmann R, Rutkowski S
2014. Klinische Pädiatrie. .

Medulloblastom mit niedrigem Risiko oder Standardrisiko: Die Studien PNET4 und PNET5
Mynarek M, von Hoff K, Kortmann R, Rutkowski S
2014. Klinische Pädiatrie. .

Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma
Northcott P, Lee C, Zichner T, Stütz A, Erkek S, Kawauchi D, Shih D, Hovestadt V, Zapatka M, Sturm D, Jones D, Kool M, Remke M, Cavalli F, Zuyderduyn S, Bader G, VandenBerg S, Esparza L, Ryzhova M, Wang W, Wittmann A, Stark S, Sieber L, Seker-Cin H, Linke L, Kratochwil F, Jäger N, Buchhalter I, Imbusch C, Zipprich G, Raeder B, Schmidt S, Diessl N, Wolf S, Wiemann S, Brors B, Lawerenz C, Eils J, Warnatz H, Risch T, Yaspo M, Weber U, Bartholomae C, von Kalle C, Turányi E, Hauser P, Sanden E, Darabi A, Siesjö P, Sterba J, Zitterbart K, Sumerauer D, van Sluis P, Versteeg R, Volckmann R, Koster J, Schuhmann M, Ebinger M, Grimes H, Robinson G, Gajjar A, Mynarek M, von Hoff K, Rutkowski S, Pietsch T, Scheurlen W, Felsberg J, Reifenberger G, Kulozik A, von Deimling A, Witt O, Eils R, Gilbertson R, Korshunov A, Taylor M, Lichter P, Korbel J, Wechsler-Reya R, Pfister S
NATURE. 2014;511(7510):428-434.

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort
Pietsch T, Schmidt R, Remke M, Korshunov A, Hovestadt V, Jones D, Felsberg J, Kaulich K, Goschzik T, Kool M, Northcott P, von Hoff K, von Bueren A, Friedrich C, Mynarek M, Skladny H, Fleischhack G, Taylor M, Cremer F, Lichter P, Faldum A, Reifenberger G, Rutkowski S, Pfister S
ACTA NEUROPATHOL. 2014;128(1):137-149.

Risikoadaptierte Behandlung von intrakraniellen Ependymomen: Ergebnisse von HIT2000 und Ausblick auf SIOP-Ependymoma II
von Hoff K, Mynarek M, Kortmann R, Rutkowski S
2014. Klinische Pädiatrie. .

2013

Normalized transcranial Doppler velocities, stroke prevention and improved pulmonary function after stem cell transplantation in children with sickle cell anemia
Mynarek M, Bettoni da Cunha Riehm C, Brinkmann F, Weißenborn K, Tell-Lüersen M, Heuft H, Maecker-Kolhoff B, Sykora K
KLIN PADIATR. 2013;225(3):127-32.

Malignancies after pediatric kidney transplantation: more than PTLD?
Mynarek M, Hussein K, Kreipe H, Maecker-Kolhoff B
PEDIATR NEPHROL. 2013.

Posttransplant lymphoproliferative disease after pediatric solid organ transplantation
Mynarek M, Schober T, Behrends U, Maecker-Kolhoff B
Clin Dev Immunol. 2013;2013:814973.

2012

Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients
Mynarek M, Tolar J, Albert M, Escolar M, Boelens J, Cowan M, Finnegan N, Glomstein A, Jacobsohn D, Kühl J, Yabe H, Kurtzberg J, Malm D, Orchard P, Klein C, Lücke T, Sykora K
BONE MARROW TRANSPL. 2012;47(3):352-9.

2011

Variable disease progression after successful stem cell transplantation: prospective follow-up investigations in eight patients with Hurler syndrome
Grigull L, Sykora K, Tenger A, Bertram H, Meyer-Marcotty M, Hartmann H, Bültmann E, Beilken A, Zivicnjak M, Mynarek M, Osthaus A, Schilke R, Kollewe K, Lücke T
PEDIATR TRANSPLANT. 2011;15(8):861-9.

Letzte Aktualisierung aus dem FIS: 20.11.2024 - 23:36 Uhr